- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06387784
Acute Beetroot Juice Supplementation in Pre-eclampsia Pregnancies (BEET_PE)
April 24, 2024 updated by: Ricardo de Carvalho Cavalli, University of Sao Paulo
Acute Effect of Beetroot Juice Supplementation in Pregnant Women With Pre-eclampsia: a Single-Blind Randomized Placebo-Controlled Trial
Pre-eclampsia is a serious condition that typically affects pregnant women after the 20th week of pregnancy, characterized by high blood pressure and damage to organs such as the kidneys and liver.
Currently, treatment options are limited, which has prompted researchers to explore alternative approaches.
One such promising alternative is dietary nitrate found in vegetables like beetroot, as nitrate can be converted into nitric oxide in the body, which helps lower blood pressure.
This study aims to determine the acute effects of nitrate-rich beetroot juice on blood pressure, several blood and salivary markers in pregnant women with pre-eclampsia.
Furthermore, the study will assess fetal blood flow using Doppler ultrasound.
The investigators want to understand the kinetics of nitrate and nitric oxide metabolites and assess the temporal dependency of the hypotensive response.
Through this investigation, the investigators seek evidence of nitrate-enriched beetroot juice as an adjunct therapy in managing pre-eclampsia.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
The study will include women diagnosed with either early-onset pre-eclampsia or late-onset pre-eclampsia, following the guidelines of the American College of Obstetricians and Gynecologists.
Participants will be required to sign informed consent forms following a thorough explanation of the study.
A total of four groups will be established, with twenty-four pregnant women randomly assigned to each group using a free online program.
In each group (early-onset and late-onset pre-eclampsia), forty-eight pregnant women will receive nitrate-enriched beetroot juice (Beet It®, James White, UK), while another forty-eight will receive an equivalent amount of placebo juice.
The trial will commence in the morning, between 7:30 and 8:30 am, after a standardized, low-nitrate breakfast provided by the hospital.
Participants will be instructed to avoid nitrate-rich foods the previous evening and will receive guidance from the project team and the hospital's nutrition service.
The hospital's nutritional team will oversee the dietary procedures.
Ambulatory blood pressure monitoring will be conducted for six hours following the ingestion of juice or placebo.
Saliva samples will be collected to assess nitrate reductase activity, and blood samples will be drawn to measure nitrate, nitrite, and nitrosothiol (nitric oxide metabolites), as well as to perform biochemical analyses of oxidative stress.
Doppler ultrasound and Doppler velocimetry evaluation will be conducted at the peak action time of nitrate, which is estimated to occur two hours post-ingestion, based on previous research.
Study Type
Interventional
Enrollment (Estimated)
96
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Priscila O Barbosa, Dr
- Phone Number: +55166021000
- Email: barbosapo@usp.br
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Pregnant women at or beyond the 20th week of gestation.
- Hospitalized at Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto.
- Diagnosed with early or late-onset pre-eclampsia confirmed by a medical professional.
- Capacity to provide written informed consent for study participation.
Exclusion Criteria:
- Multiple pregnancies.
- Uncontrolled arterial hypertension (Systolic Blood Pressure > 160 mmHg or Diastolic Blood Pressure > 100 mmHg).
- Pregnant women with a body mass index > 40 kg/m²
- Severe gestational complications.
- History of food allergy with hypersensitivity to beetroot.
- Smokers.
- Chronic alcohol consumption.
- Use of medications, except for antihypertensive.
- Diagnosis of renal or hepatic disease affecting nitrate metabolism.
- Cardiac conditions such as moderate to severe congestive heart failure and coronary artery disease.
- Pre-existing type 1 or type 2 diabetes.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Early-onset pre-eclampsia beetroot juice
A single dose of 70 ml of nitrate-rich beetroot juice containing 400 mg of nitrate.
|
In the morning, pregnant women with pre-eclampsia will consume a single dose of 70 ml of nitrate-rich beetroot juice containing 400 mg of nitrate.
Participants will be monitored to assess the acute effects of nitrate intake for 6 hours.
|
Placebo Comparator: Early-onset pre-eclampsia placebo juice
A single dose of 70 ml of a formulation with a similar taste, smell, and texture.
|
In the morning, pregnant women with pre-eclampsia will consume 70 ml of a placebo juice.
The placebo juice will be similar in appearance and taste to the nitrate-rich beetroot juice.
Participants will be monitored to compare the acute effects of beetroot juice with the placebo intake for 6 hours.
|
Experimental: Late-onset pre-eclampsia beetroot juice
A single dose of 70 ml of nitrate-rich beetroot juice containing 400 mg of nitrate.
|
In the morning, pregnant women with pre-eclampsia will consume a single dose of 70 ml of nitrate-rich beetroot juice containing 400 mg of nitrate.
Participants will be monitored to assess the acute effects of nitrate intake for 6 hours.
|
Placebo Comparator: Late-onset pre-eclampsia placebo juice
A single dose of 70 ml of a formulation with a similar taste, smell, and texture.
|
In the morning, pregnant women with pre-eclampsia will consume 70 ml of a placebo juice.
The placebo juice will be similar in appearance and taste to the nitrate-rich beetroot juice.
Participants will be monitored to compare the acute effects of beetroot juice with the placebo intake for 6 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute Effect of Beetroot Juice Supplementation on Blood Pressure
Time Frame: Every 30 minutes up to 6 hours post-supplementation.
|
Assessment of the acute effect of beetroot juice supplementation on blood pressure (measured in millimetres of mercury - mmHg) in pregnant women diagnosed with early and late-onset pre-eclampsia, measured every 30 minutes up to 6 hours post-supplementation, starting 30 minutes before ingestion, compared to a placebo group.
|
Every 30 minutes up to 6 hours post-supplementation.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma Concentrations of Nitric Oxide Metabolites
Time Frame: At baseline and up to 6 hours post-supplementation.
|
Assessment of plasma concentrations of nitric oxide metabolites (nitrite, nitrate and nitrosothiol) in pregnant women diagnosed with pre-eclampsia, comparing those receiving beetroot juice supplementation and those receiving placebo.
|
At baseline and up to 6 hours post-supplementation.
|
Concentration of Salivary Nitrate Reductase Enzyme
Time Frame: At baseline and up to 6 hours post-supplementation.
|
Assessment of the activity of the nitrate reductase enzyme in saliva in each study group.
|
At baseline and up to 6 hours post-supplementation.
|
Plasma Lipid Peroxidation Levels
Time Frame: At baseline and up to 6 hours post-supplementation.
|
Assessment of the degree of lipid peroxidation, measured by the level of malondialdehyde in each study group.
|
At baseline and up to 6 hours post-supplementation.
|
Concentration of Total Antioxidant Capacity in Plasma
Time Frame: At baseline and up to 6 hours post-supplementation.
|
Determination of the plasma concentration of total antioxidant capacity of plasma, measured in Trolox equivalent antioxidant capacity, in each study group.
|
At baseline and up to 6 hours post-supplementation.
|
Maternal Blood Flow Velocity
Time Frame: 2 hours post-supplementation of beetroot juice or placebo.
|
Maternal blood flow velocity will be measured in centimeters per second (cm/s) using Doppler ultrasound, in each study group.
|
2 hours post-supplementation of beetroot juice or placebo.
|
Fetal Heart Rate
Time Frame: 2 hours post-supplementation of beetroot juice or placebo.
|
Fetal heart rate will be measured in beats per minute (bpm) using Doppler ultrasound, in each study group.
|
2 hours post-supplementation of beetroot juice or placebo.
|
Umbilical Arterial Pulsatility Index
Time Frame: 2 hours post-supplementation of beetroot juice or placebo.
|
The umbilical arterial pulsatility index will be calculated and reported as a percentile, in each group.
|
2 hours post-supplementation of beetroot juice or placebo.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Ricardo C Cavalli, Dr, Medical School of Ribeirao Preto, USP
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2024
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
April 16, 2024
First Submitted That Met QC Criteria
April 24, 2024
First Posted (Actual)
April 29, 2024
Study Record Updates
Last Update Posted (Actual)
April 29, 2024
Last Update Submitted That Met QC Criteria
April 24, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2024/823
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
We will provide access to individual de-identified participant data and related study documents upon request from qualified researchers, subject to certain criteria, conditions, and exceptions.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pre-Eclampsia
-
Assiut UniversityNot yet recruitingPre-eclampsia Aggravated | Pre-Eclampsia; Complicating Pregnancy
-
Dow University of Health SciencesCompletedPre-eclampsia | Hypertension, Pregnancy Induced | Hydralazine Adverse Reaction | Pre-eclampsia Superimposed Pre-existing HypertensionPakistan
-
University of WashingtonUniversity of Cape TownCompletedSevere Pre-eclampsia | Mild Pre-eclampsiaSouth Africa, United States
-
William Marsh Rice UniversityUniversity of MalawiCompleted
-
Duke UniversityTerminated
-
William Marsh Rice UniversityCompletedPre EclampsiaUnited States
-
Oxford University Hospitals NHS TrustUniversity of CambridgeTerminated
-
Novartis PharmaceuticalsTerminatedPre-eclampsiaItaly, United States
-
Ain Shams UniversityCompleted
-
Nantes University HospitalCompleted
Clinical Trials on Beetroot juice
-
Universidad Francisco de VitoriaUniversity of Alcala; University of SevilleCompleted
-
Bangor UniversityCompleted
-
University Hospital, GhentUniversity GhentTerminated
-
Queen Mary University of LondonCompleted
-
University of ManchesterCompleted
-
University of Colorado, BoulderRecruitingChronic Kidney DiseaseUnited States
-
Penn State UniversityActive, not recruitingMetabolic SyndromeUnited States
-
Wake Forest University Health SciencesCompletedStroke | Ischemic Stroke | Cerebrovascular AccidentUnited States
-
Universidad Autonoma de MadridUniversidad Politecnica de Madrid; Camilo Jose Cela UniversityCompletedNitrates | Nutrition | Physical Performance | Sport Physiology | Elite Athletes
-
University of ReadingNot yet recruitingPost MenopausalUnited Kingdom